Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens

This study aimed to explore changes in hepatic and renal function indices in chronic hepatitis C (CHC) patients treated with direct-acting antivirals (DAAs). Forty-three CHC patients treated with sofosbuvir (SOF)-containing regimens were enrolled. At the end of treatment, the estimated glomerular filtration rate (eGFR) level was significantly decreased and the serum creatinine (Scr) and uric acid (UA) levels were significantly increased compared with baseline levels (eGFR: 86.7 ± 20.4 vs 80.5 ± 21.3, P(01) = 0.005; Scr: 83.9 ± 19.1 vs 89.6 ± 21.1, P(01) < 0.001; UA: 323.7± 86.2 vs 358.5 ± 93.2, P(01) < 0.001); no significant improvements were observed at 24 w post-treatment (eGFR: 86.7 ± 20.4 vs 81.4 ± 18.6, P(02) = 0.013; Scr: 83.6 ± 17.9 vs 87.9 ± 18.3, P(02) = 0.014; UA: 320.8 ± 76.3 vs 349.3 ± 91.0, P(02) = 0.004). When the patients were grouped by liver conditions, non-cirrhotic patients and cirrhotic patients had decreased eGFR levels and increased Scr levels at the end of treatment; at 24 w post-treatment, the eGFR and Scr levels were significantly improved in non-cirrhotic patients (88.4 ± 21.7 vs 83.8 ± 18.5, P(02) = 0.142; 84.4 ± 20.4 vs 87.0 ± 16.9, P(02) = 0.088), while no obvious improvements were observed in cirrhotic patients (84.3 ± 18.7 vs 78.1 ± 18.6, P(02) = 0.002; 83.2 ± 17.7 vs 89.2 ± 20.6, P(02) = 0.006). Clinical physicians should closely monitor renal function in patients treated with SOF-containing regimens, especially in cirrhotic patients.